^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SNV-001

    i
    Other names: SNV-001
    Associations

    News

    Trials
    Company:
    Synnovation Therap
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Discovery of a potent and selective PARP1 inhibitor and trapper with anti-tumor activities in HRD tumors (AACR 2023)
    Furthermore, SNV-001 showed dose-dependent tumor growth inhibition using low daily doses with greater efficacy compared to olaparib dosed at 100 mg/kg once daily. In the cohort receiving a higher dose of SNV-001, all animals showed complete regression after 35 days of treatment without any clinical signs of toxicity.In summary, we have discovered SNV-001, a potent and selective PARP1 inhibitor and trapper that shows excellent activity against cancer models with HRD in vitro and in vivo. These data support advancement of SNV-001 into clinical development for patients with tumors characterized by HRD.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    BRCA1 mutation • HRD • BRCA wild-type • HRD + BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • SNV-001